Navigation Links
MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
Date:5/3/2011

fiscal 2011 full year operating expenses, excluding non-cash charges such as stock-based compensation and depreciation, to be approximately $50 to $55 million. In addition, the Company currently anticipates capital expenditures in 2011 to be approximately $4 to $5 million. As previously disclosed, the Company anticipates loan payments of approximately $8 million in 2011 related to a working capital loan. Collaboration revenues are estimated to be approximately $65 million in 2011. This estimate includes amortization of the upfront payment received in February 2011 and a milestone payment that the Company would be eligible to receive in 2011 under its collaboration agreement with Allergan, if a certain milestone is met.

About MAP PharmaceuticalsMAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX, an orally inhaled investigational drug for the acute treatment of migraine. The Company has reported positive results from its Phase 3 trial of LEVADEX and has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate and MAP Pharmaceuticals' expected cash requirements during 2011 describe
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... August 29, 2014 According to a new ... the global orthobiologics market was valued at USD 3,754.6 million ... USD 5,519.9million in 2019at a CAGR of 5.9% from 2013 ... years and above is afflicted by bone and joint disorders, ... year 2020. This has and will continue to increase the ...
(Date:8/29/2014)... 2014 Pittcon is pleased to announce ... Koichiro Matsuda, Horiba Scientific, have organized a session on ... JASIS , Asia’s largest analytical and scientific instruments ... Messe, Japan. , The four speakers in this ... Single Molecules to Single Cells” will present their use ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4
... BEIJING, Nov. 13 /PRNewswire-Asia/ -- IVT Corporation announced today ... Mobile Asia Congress,in Hong Kong on Nov. 18-19, at Booth ... monitoring from home, reducing risk of diseases and,assisting with emergency ... ) , It includes: , ...
... An experiment by college students that will study how ... shuttle Atlantis. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) ... in Houston developed the experiment that will fly as part ... at 2:28 p.m. EST on Nov. 16 from NASA,s Kennedy ...
... ... addresses common problems associated with purification of recombinant proteins by enabling the delivery ... ... (PRWEB) November 12, 2009 -- The recently released Promega HaloTag® Protein Purification System ...
Cached Biology Technology:IVT will Demo Mobile Health System at GSMA Mobile Asia Congress and CES 2010 2Students Send Microbe Experiment on Space Shuttle Atlantis 2Students Send Microbe Experiment on Space Shuttle Atlantis 3Promega HaloTag Protein Purification System Makes it Easier to Purify Difficult-to-Express Proteins 2
(Date:8/29/2014)... such as the prolific bloomer Emiliania huxleyi , ... discovered. The finding contradicts the common view that ... on scarce supplies of thiamine in the ocean to ... about the ocean," says CIFAR Senior Fellow Alexandra ... paper with CIFAR fellows John Archibald (Dalhousie ...
(Date:8/28/2014)... is pleased to announce the selection of Dr. Fred ... Membership acknowledges those who have served ESA for at ... of the Society that has reached an extraordinary level. ... Governing Board and then voted on by the ESA ... Ceremony at Entomology 2014, ESA,s Annual Meeting in Portland, ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society of Human Genetics from October 18 22, ... meant to promote the entry of students, post doctorates ... the basic science community and to encourage the participation ... Genetics. This year MARC conferred 16 awards totaling ...
Breaking Biology News(10 mins):Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
... Thousands of Americans this year will be diagnosed with a ... muscle disorders (TMJD, formerly called TMJ). Because of the ... no way to determine whether their patients will get better ... help is on the way. Scientists affiliated with a ...
... Coneheads (or Protura) is a group of primitive "insects" ... in 1907 by the famous Italian zoologist Filippo Silvestri, ... Dodero from soil samples, taken from the grounds of ... In the two following years Antonio Berlese, another very ...
... between India and Germany has intensified. This was highlighted ... (DFG, German Research Foundation), during a visit to India ... New Delhi on Nov. 3 and 4, 2011. ... a new dimension," said the DFG President in a ...
Cached Biology News:Study evaluates risk factors for chronic TMJD 2Study evaluates risk factors for chronic TMJD 3Study evaluates risk factors for chronic TMJD 4Study evaluates risk factors for chronic TMJD 5Scientific collaboration between India and Germany reaches new dimension 2